The Food and Drug Administration (FDA) evaluated LifeStart Fertility Center in Agoura Hills on April 22, reviewing practices related to human cellular, tissue, and gene therapies, according to data posted on the FDA’s website.
The inspection’s final report advised that LifeStart Fertility Center did not need to implement any corrections to its management operations.
The FDA regularly inspects facilities throughout the country to ensure workplaces and their products comply with regulations intended to protect public health. The agency publicly shares the results of these inspections.
The agency’s website states that the FDA is chiefly responsible for overseeing the safety and quality of drugs, biological products, medical devices, and tobacco products for both humans and animals.
Information in this article was obtained from the U.S. Food and Drug Administration. The source data can be found here.
